BPTH · Bio-Path Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s available cash and cash equivalents of $0.1 million at March 31, 2026 will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months from the date of issuance of these consolidated financial statements. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2024-07-30 | Cleaver Heath |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 2,000 shares, based on continuing service to Bio-PathHoldings, Inc. |
Common Stock Option (right to buy)
|
2,000 |
| 2024-07-30 | Nielsen Peter Henry |
Director, President, CEO & CFO |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 25,000 shares vesting on the first anniversary of July 30, 2024, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 25,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
25,000 |
| 2024-07-30 | Aubert Paul |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 2,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
2,000 |
| 2024-07-30 | Sherwood Aline |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 2,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
2,000 |
| 2024-07-30 | MORRIS DOUGLAS P |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth ( 1/4) of the 3,537 shares vesting on the first anniversary of July 30, 2024, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 3,537 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
3,537 |
| 2023-05-02 | Cleaver Heath |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2023-05-02 | Aubert Paul |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2023-05-02 | MORRIS DOUGLAS P |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 13,000 shares vesting on the first anniversary of May 2, 2023, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 13,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
13,000 |
| 2023-05-02 | Sherwood Aline |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2023-05-02 | Nielsen Peter Henry |
Director, President, CEO & CFO |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 105,000 shares vesting on the first anniversary of May 2, 2023, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 105,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
105,000 |
| 2022-03-31 | Sherwood Aline |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2022-03-28 | Aubert Paul |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2022-03-28 | MORRIS DOUGLAS P |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 11,000 shares vesting on the first anniversary of March 28, 2022, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 11,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
11,000 |
| 2022-03-28 | Cleaver Heath |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2022-03-23 | Nielsen Peter Henry |
Director, President, CEO & CFO |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 90,000 shares vesting on the first anniversary of March 23, 2022, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 90,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
90,000 |
| 2021-03-31 | MORRIS DOUGLAS P |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 13,000 shares vesting on the first anniversary of March 31, 2021, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 13,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
13,000 |
| 2021-03-31 | Nielsen Peter Henry |
Director, President, CEO & CFO |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 100,000 shares vesting on the first anniversary of March 31, 2021, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 100,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
100,000 |
| 2021-03-31 | Cleaver Heath |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2021-03-31 | Molsbergen Tamaro Martina |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2021-03-31 | Aubert Paul |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2020-06-16 | Nielsen Peter Henry |
Director, President, CEO & CFO |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 85,000 shares vesting on the first anniversary of June 16, 2020, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 85,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
85,000 |
| 2020-03-27 | MORRIS DOUGLAS P |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 10,000 shares vesting on the first anniversary of March 27, 2020, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2020-03-27 | Molsbergen Tamaro Martina |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2020-03-27 | Cleaver Heath |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2020-03-27 | Aubert Paul |
Director |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
10,000 |
| 2020-03-18 | Nielsen Peter Henry |
Director, President, CEO & CFO |
Award↑
Filing footnotes — Common Stock Option (right to buy) (Direct)
This option vests over a four-year period, with one-fourth (1/4) of the 15,000 shares vesting on the first anniversary of March 18, 2020, and the remaining shares vesting thereafter in equal monthly increments equal to one-forty-eighth (1/48) of the 15,000 shares, based on continuing service to Bio-Path Holdings, Inc. |
Common Stock Option (right to buy)
|
15,000 |